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OBJECTIVE The purpose of this study is to report prospectively the results of six-month follow-up of
permanent left ventricular (LV) based pacing in patients with severe congestive heart failure
(CHF) and left bundle branch block (LBBB).
BACKGROUND Left ventricular pacing alone has been demonstrated to result in identical improvement
compared to biventricular pacing (BiV) during acute hemodynamic evaluation in patients
with advanced CHF and LBBB. However, to our knowledge, the clinical outcome during
permanent LV pacing alone versus BiV pacing mode has not been evaluated.
METHODS Pacing configuration (LV or BiV) was selected according to the physician’s preference.
Patient evaluation was performed at baseline and at six months.
RESULTS Thirty-three patients with advanced CHF and LBBB were included. Baseline characteristics
of LV (18 patients) and BiV (15 patients) pacing groups were similar. During the six-month
follow-up period, seven patients died three BiV and four LV). In the surviving patients at 6
months, 8 of 14 patients in the LV group and 9 of 12 in the BiV group were in New York
Heart Association class I or II (p 0.39). No significant difference was observed between the
two groups in terms of objective parameters except for LV end-diastolic diameter decrease
(4.4 mm in BiV group vs. 0.7 mm in LV group; p  0.04).
CONCLUSION At six-month follow-up, a trend toward improvement was observed in objective parameters
in patients with severe CHF and LBBB following LV-based pacing. The two pacing modes
(LV and BiV) were associated with almost equivalent improvement of subjective and objective
parameters. (J Am Coll Cardiol 2001;38:1966–70) © 2001 by the American College of
Cardiology
Congestive heart failure (CHF) is a major health care
problem, associated with a high mortality rate reaching
almost 50% at one year in New York Heart Association
(NYHA) class IV patients (1). Moreover, the quality of life
of patients with CHF remains poor despite optimal man-
agement. Some pharmacologic agents such as angiotensin-
converting enzyme inhibitors, beta-blockers or spironolac-
tone were found to improve survival in patients with CHF;
others such as digoxin only ameliorate the quality of life (2).
Recently, permanent cardiac pacing has been suggested as
an adjuvant therapy for patients with severe CHF and wide
QRS complexes (3–8). This treatment was based initially
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on the hypothesis that resynchronization of left and right
ventricular contractions might restore left ventricular (LV)
function (6,9). Left ventricular–based pacing was evaluated
by several groups using uncontrolled studies and the first
acute and short-term evaluations demonstrated encouraging
results (3–8). Interestingly, LV pacing alone has exhibited
comparable improvement to biventricular (BiV) pacing
during acute hemodynamic evaluation in patients with
advanced CHF and left bundle branch block (LBBB)
(3–5,8). Nevertheless, clinical follow-up during permanent
LV pacing is unknown. This study aimed to evaluate the
six-month clinical follow-up of permanent LV pacing com-
pared to BiV pacing in patients with CHF and LBBB.
METHODS
This prospective comparative observational study was con-
ducted on consecutive patients with severe CHF and LBBB
and no class I indication for permanent pacing. Entry in the
study was decided in two steps: first, patients 80 years of
age with LBBB (QRS duration 140 ms) and severe CHF
were selected for hemodynamic evaluation. The ischemic or
nonischemic nature of their cardiomyopathy was deter-
mined using coronary angiography. Pharmacologic treat-
ment was considered optimal and unchanged for at least
three months. The main exclusion criteria were a recent
myocardial infarction (6 months), or coronary artery
bypass surgery and a limited life expectancy (1 year) due to
disease other than CHF. Potential candidates for heart
transplantation were also excluded. Left ventricular or BiV
pacing mode was determined according to the physician’s
preference (mainly BiV at the beginning of our experience).
Study protocol. Patients evaluation included the following:
physical examination, electrocardiogram, blood test, echo-
cardiography, radionuclide angiography, 6-min walk test
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and peak oxygen consumption (VO2) evaluation using a
treadmill test with the following protocol: after a 2-min
warm-up at level 0, the work-load increase was proceeded
by 20-W steps every 2 min until occurrence of severe
dyspnea, chest pain, fatigue or inability to continue the test.
Thereafter, patients underwent a hemodynamic evaluation
as previously described (3). Briefly, pulmonary artery capil-
lary wedge pressure (PCWP) and “V” wave were obtained
by advancing a catheter into a distal branch of the pulmo-
nary artery. A femoral artery catheter was used for blood
pressure recordings. In patients in sinus rhythm, two bipolar
catheters were positioned transvenously in the high right
atrium and the right ventricular (RV) apex. A third bipolar
catheter was advanced via retrograde approach through the
aortic valve to pace the endocardial part of the LV lateral
free wall. Pacing was performed with an atrioventricular
(AV) delay of 100 ms, in order to achieve complete capture
of the ventricles (pacing output of 3 V at 0.5 ms). For
patients in sinus rhythm, pacing was performed in the atrial
synchronous ventricular inhibited pacing (VDD) mode for
3 min before data acquisition in a random order at the RV
apex alone, the left lateral free wall alone and at both sites
simultaneously with the left lateral free wall being the anode
and RV apex being the cathode. In patients in atrial
fibrillation, the ventricular demand pacing (VVI) pacing
mode was used, and the pacing rate was programmed 10
beats/min above the spontaneous mean ventricular rate.
Baseline data recorded in all patients included mean
arterial blood pressure, PCWP and “V” wave amplitude
(mm Hg). An immediate improvement of 20% of at least
one of these hemodynamic parameters in comparison to
baseline values during LV-based pacing was required for
final inclusion for permanent pacing. The pacing mode, LV
or BiV was left to the physician’s decision and also accord-
ing to technical difficulty during implantation. Patients were
aware of the possibility of having one or two leads and were
informed about the clinical trial.
A transvenous approach for permanent LV-based pacing
was used (10). Briefly, a “long” sheath was inserted into the
coronary sinus and the pacing electrode (unipolar lead,
Medtronic 4023/65 cm, Medtronic Inc., Minneapolis,
Minnesota; or St Jude 1055K/75 cm, St. Jude Medical,
Sylmar, California) was advanced though the long sheath
into one of its branches and very preferentially in a lateral
vein successfully attained in most cases. In the BiV pacing
group, the RV lead (bipolar lead, St. Jude 1470T/55 cm)
was placed at the apex. For patients with BiV pacing, the
ventricular leads were connected to the ventricular port of a
standard dual-chamber generator through a Y connector
(lead extension IS-1, 3.2 mm, SYCB 53415, Sulzer Medica
Osypka, Grenzach-Wyhlen, Germany).
Follow-up. Clinical follow-up was performed at 1 and 6
months. At every follow-up visit, clinical parameters, 6-min
walk test, echocardiography, radionuclide angiography and
peak VO2 were determined. At each visit, interrogation of
the pacemaker confirmed that ventricular pacing was largely
predominant (95% of the time). Final pacemaker repro-
gramming was individually performed at the end of the first
month using echocardiographic determination of the best
AV interval (generally 100 ms).
Statistical analysis. Data were expressed as mean  stan-
dard deviation or as percentage. Chi-square test was used to
compare categorical variables and paired or unpaired Stu-
dent t test (two-tailed) for continuous variables. Statistical
significance was achieved at p  0.05 level. Statistical
analysis was performed using StatView 4.5 software (Abacus
Concepts, Inc.).
RESULTS
Study population. Thirty-three patients fulfilled the inclu-
sion criteria. As shown in Table 1, LV (n  18) and BiV
(n  15) pacing groups had similar demographics charac-
teristics. Patients included in this study presented the usual
clinical parameters of advanced CHF regardless of the
NYHA functional class severity (20 in class IV): the mean
left ventricular ejection fraction (LVEF) was 23.4 7.4 and
the mean peak VO2 was 11.7  3.1 ml/kg per min.
Evaluation of the 6-month status in the two study
groups. During follow-up, seven patients (21%) died (three
BiV, four LV). Death was sudden in one patient (LV) and
Abbreviations and Acronyms
AV  atrioventricular
BiV  biventricular (pacing)
CHF  congestive heart failure
LBBB  left bundle branch block
LV  left ventricular (pacing)
LVEDD  left ventricular end-diastolic diameter
LVEF  left ventricular ejection fraction
MR  mitral regurgitation
NYHA  New York Heart Association
PCWP  pulmonary capillary wedge pressure
RV  right ventricular
VO2  oxygen consumption
Table 1. Baseline Patient Characteristics
LV
(n  18)
BiV
(n  15)
p
Value
Gender ratio (M/F) 13/5 13/2 0.55
Dilated/ischemic cardiomyopathy (n) 12/6 8/7 0.43
Atrial fibrillation/sinus rhythm (n) 10/8 5/10 0.20
NYHA class III/IV (n) 6/12 7/8 0.43
Age (yr) 69  6 67  6 0.46
QRS duration (ms) 183  24 187  37 0.69
LVEDD (mm) 72.7  7.6 73.4  7.3 0.81
LVEF (%) 24.7  7.6 22.1  7.1 0.31
MR area (cm2) 13.1  6.0 10.5  6.2 0.26
Six-min walk distance (m) 395  109 412  74 0.63
Peak VO2 (ml/kg per min) 11.7  3.5 11.7  2.7 0.99
BiV  biventricular pacing; LV  left ventricular pacing alone; LVEDD  left
ventricular end-diastolic diameter; LVEF  left ventricular ejection fraction; MR 
mitral regurgitation; NYHA  New York Heart Association; VO2  oxygen
consumption.
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due to progressive deterioration of CHF in the other six
patients. Surviving patients (n  26) showed no significant
difference in clinical characteristics when compared to the
whole population (n  33). As shown in Table 2, baseline
clinical characteristics in surviving patients were identical in
the two groups. The LV group included more patients with
dilated cardiomyopathy (p  0.51), whereas, atrial fibrilla-
tion was more frequently observed in the BiV pacing group
(p  0.64). The 6-min walk distance and the LV end-
diastolic diameter (LVEDD) were also greater in the BiV
pacing group, but the difference did not reach statistical
significance (p  0.37). After six months of permanent
pacing, overall improvement from baseline was observed
(Table 3) and the final values at six months were very similar
in the two groups.
Comparison of benefits at 6-month follow-up in the two
groups. At six months, NYHA functional class improve-
ment was clearly observed in the two pacing groups (Table
3). In fact, eight and nine patients in the LV and BiV
groups, respectively, moved to NYHA class I and II. Only
three patients from each group remained in NYHA class
IV. No significant difference between LV and BiV groups
was observed for the NYHA functional class distribution.
Mean improvements of the functional class were 1.1 and
1.3, respectively, for the LV and BiV groups (p  0.63).
The evolution of the other parameters recorded during
follow-up was variable (Table 3): the LVEDD decreased
more significantly in the BiV group (p  0.04). The LVEF
tended to improve more in the BiV group than in the LV
group (p  0.06); conversely, mitral regurgitation (MR)
area, 6-min walk distance and peak VO2 variations remained
in the same range in the two study groups. The QRS
duration obtained immediately after pacemaker implanta-
tion showed a greater decrease in the BiV group than in the
LV group (19 ms vs. 1 ms, p  0.09). Interestingly, the
LVEF improvement was significantly correlated to the QRS
duration diminution in the BiV group (r  0.67, p  0.02)
but not in the LV group (r  0.15, p  0.66).
Safety. No significant difference in average fluoroscopic
times during pacemaker implantation was observed between
the LV group (36  18 min) and the BiV group (39 
24 min; p  0.81). Only one serious adverse event (pocket
infection six months later) occurred in a patient included in
the BiV pacing group, with a final favorable outcome after
implantation of a new pacemaker on the other side. Lead
dislodgment requiring repositioning occurred in two pa-
tients included in the LV pacing group and in one patient
from the BiV pacing group.
DISCUSSION
Although all acute hemodynamic studies comparing LV
pacing alone versus BiV pacing have shown equivalent (3) or
even better results (4,5) with LV pacing alone, comparative
long-term data are lacking in current series and only results
of studies with permanent BiV pacing are reported. Two
explanations could be proposed: 1) BiV was the first
reported pacing mode having demonstrated long-term ben-
efit in patients with severe CHF and long QRS duration
and physicians continue to ignore the results of acute series;
and 2) “resynchronization” of the two ventricles was con-
sidered, without any demonstration, as a prerequisite for
improvement of the conditions of such patients. However, it
is clear that from a technical, economical and perhaps safety
point of view that it is easier and better to implant two
rather than three leads. The absence of clear evidence for the
superiority of BiV pacing led us to leave the pacing mode to
the investigator’s discretion.
Rationale for the present study design. This prospective
study was considered as a pilot study. The follow-up was
limited to six months to allow inclusion of a sufficient
number of patients due to the high mortality rate associated
with NYHA class IV.
Patients included had to demonstrate a significant im-
provement during acute hemodynamic evaluation with ei-
ther LV or BiV pacing mode. We know of no data to
substantiate this attitude but, at the beginning of our
experience, we believed that it was more ethical to consider
LV-based pacing only in such patients. Nevertheless, this
prerequisite is not a bias in the comparison of LV and BiV
Table 2. Comparative Baseline Characteristics in
Surviving Patients
LV
(n  14)
BiV
(n  12)
p
Value
Gender ratio (M/F) 10/4 10/2 0.80
Dilated/ischemic cardiomyopathy (n) 10/4 6/6 0.51
Atrial fibrillation/sinus rhythm (n) 7/7 8/4 0.64
NYHA class III/IV (n) 6/8 5/7 0.95
Age (yr) 68  9 67  4 0.60
QRS duration (ms) 180  25 189  38 0.50
LVEDD (mm) 71.9  6.0 74.1  6.4 0.37
LVEF (%) 24.5  7.2 22.8  7.2 0.55
MR area (cm2) 12.5  5.9 10.0  5.2 0.26
6-min walk distance (m) 409  88 423  72 0.68
Peak VO2 (ml/kg per min) 11.9  3.8 11.4  2.8 0.72
Abbreviations as in Table 1.
Table 3. Six-Month Clinical Improvement in Surviving Patients
LV
Variation
(n  14)
BiV
Variation
(n  12)
p
Value
NYHA
Class I 3 3
Class II 5 6 0.39
Class III 3 0
Class IV 3 3
QRS duration (ms) 1  25 19  31 0.09
LVEDD (mm) 0.7  3.5 4.4  4.6 0.04
LVEF (%) 1.2  4.9 5.7  6.3 0.06
MR area (cm2) 5.3  5.6 4.2  4.1 0.6
6-min walk distance (m) 15  81 58  103 0.3
VO2 (ml/kg per min) 1.1  2.4 2.5  3.7 0.3
Abbreviations as in Table 1.
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patients as they were compared after the same selection
procedure and we disregarded the result of the acute
evaluation regarding the choice of chronic pacing modality.
Moreover, in the vast majority of cases, when hemodynamic
improvement was observed, it was present with the two
pacing modes.
Comparison between the two pacing groups. The base-
line characteristics of the two groups were very close, even
after exclusion of patients who died during the first six
months. Patients were severely sick with a mean LVEF of
25%. The QRS duration was very long (180 ms),
especially in the BiV group. After 6 months, 7 patients had
died in the study group. This high mortality rate has to be
related to the NYHA class of the patients included and was
certainly predictable. Of note, the mortality rate was iden-
tical in both groups and only one patient died suddenly. Due
to the limited number of events, no definite conclusion
regarding survival could be drawn from these data.
At six months, the functional status of the surviving
patients was significantly ameliorated from baseline and was
similar in both groups. Such results have already been
reported during long-term studies of BiV pacing (11) but
not up to now after permanent LV pacing alone. More
objective parameters such as LVEDD, LVEF, peak VO2,
6-min walk distance and MR area were also improved
between baseline and six months, not only in the BiV group
but also in the LV group.
Comparison of benefits in the two groups. Although the
two groups improved in most of the studied parameters
between baseline and six months, improvement tended to be
greater in the BiV group for LVEDD and LVEF, whereas
it remained similar in the two groups for the other param-
eters and particularly for those exploring quality of life.
In these small groups of patients, safety was not a
problem, although one patient with BiV pacing presented
with a pacemaker pocket infection that required explanta-
tion of the pacing lead system and re-implantation of a new
system on the other side with an excellent result.
Hypothesis for the improvement during LV-based pac-
ing. It is clear from this study that although the conditions
of some patients did not improve, the majority did so and
sometimes very impressively. This long-term improvement
occurred during BiV pacing but also during LV pacing
alone in accordance with the results of acute hemodynamic
studies. These results suggest that the most important
phenomenon that leads to the improvement of LV function
in those patients with wide QRS complexes is the LV
stimulation and not the resynchronization of the two
ventricles. One could argue that in patients in sinus rhythm,
the QRS complex is a fusion between the impulse originat-
ing from the left lateral pacing electrode and the impulse
traveling through the AV node, preferentially to the RV
resulting in a “hidden” resynchronization. This hypothesis
seems unlikely as: 1) the programmed AV delay is short and
probably a major part of the RV was depolarized from the
left, and 2) more importantly, the improvement was found
to be equivalent in a previous acute study, in patients with
atrial fibrillation paced either in the LV alone or in both
ventricles (12). If resynchronization of the two ventricles is
not the key mechanism, the beneficial effect may result from
the fact that LV pacing with or without RV pacing
eliminates the deleterious effects of LBBB (13). Biventricu-
lar pacing results in right bundle branch block and LV
pacing alone leads to more pronounced RV conduction
disturbance. Whether this induced right bundle branch
block has long-term hemodynamic deleterious effects re-
mains unknown, but acute data on hemodynamics of LBBB
are not in favor of this hypothesis. The present study does
not bring any definite argument to think so, although
LVEDD and LVEF improved more in the BiV group than
in the LV group, but their baseline value was worse in the
former group.
Study limitations. The small number of patients included
is certainly a limitation and a more extensive study is needed
to confirm these data. The most obvious limitation is the
absence of randomization, but the baseline values were very
close in the two groups indicating that their comparison is
valid. The location of the LV lead is questionable but has to
satisfy many different and generally incompatible parame-
ters such as pacing thresholds, anatomy of the tributaries of
the coronary sinus, stability of the electrode and best
electrophysiologic site, a concept intuitively linked to the
most delayed recorded ventricular potential. Ideally, deter-
mination of the latest potential requires multiple attempts
from different sites, which is time-consuming and anatomy-
limited; however, new technologies may improve this re-
search. In the present study, we attempted in every case to
implant the lead in a “lateral” vein and to avoid the posterior
or very anterior branches. We succeeded in the vast majority
of the cases, but whether the final site was optimal remains
uncertain.
CONCLUSIONS
This study, in agreement with previously published series,
shows that permanent BiV pacing improves subjective and
objective parameters at 6 months. The new data suggest that
LV pacing alone achieves the same goal. Although a trend
exists in favor of BiV pacing for the improvement of some
parameters (poorer at baseline in this subgroup of patients),
most are equivalent and the clinical status is identical in the
two pacing modalities at 6 months. However, these results
should be interpreted cautiously and longer follow-up may
disclose significant differences in favor of BiV pacing. As
there are no published series (to our knowledge) demon-
strating that permanent BiV pacing is significantly better
than LV pacing alone and even if this study has limitations,
it gives rationale to compare in a randomized study the
sophisticated BiV pacing and the more simple LV pacing in
patients with CHF and LBBB.
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